Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 768 matching trials from the live ClinicalTrials.gov search.

Filters: "castration-resistant" Clear all

Conditions: Metastatic Castration-Sensitive Prostate Cancer
Interventions: Saruparib, Placebo, Abiraterone Acetate, Darolutamide, Enzalutamide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Male only
Enrollment: 1,898 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 71
States / cities: Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 63 more

Conditions: Metastatic Castration Resistant Prostate Cancer
Interventions: Rinzimetostat, Darolutamide, Enzalutamide, Docetaxel; Drug
Lead sponsor: ORIC Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 14
States / cities: Glendale, California • Coral Springs, Florida • Jeffersonville, Indiana + 11 more

Conditions: Prostate Neoplasms
Interventions: Abiraterone acetate, Prednisone; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostatic Neoplasms
Interventions: 18F-Sodium Fluoride (NaF); Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Male only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Prostate Cancer
Interventions: Darolutamide(Nubeqa, BAY1841788); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 805 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 24
States / cities: Homewood, Alabama • Tucson, Arizona • San Diego, California + 21 more

Conditions: Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Prostate Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Prostate Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Triple-Negative Breast Carcinoma, Unresectable Solid Neoplasm
Interventions: Docetaxel, Laboratory Biomarker Analysis, Pharmacological Study, PI3Kbeta Inhibitor AZD8186; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 8
States / cities: Aurora, Colorado • Baltimore, Maryland • Bethesda, Maryland + 4 more

Conditions: Prostate Carcinoma, Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8
Interventions: Computed Tomography, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan, Positron Emission Tomography, PSMA PET Scan, Questionnaire Administration, Single Photon Emission Computed Tomography; Procedure · Other · Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Prostate Cancer
Interventions: Enzalutamide, Relacorilant; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Male only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Prostatic Neoplasm
Interventions: AAA617, AAA517, Piflufolastat F 18, ARPI, ADT, Best supportive care; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 10
States / cities: Denver, Colorado • Athens, Georgia • Indianapolis, Indiana + 7 more

Conditions: Biochemically Recurrent Prostate Cancer
Interventions: Darolutamide (BAY1841788, Nubeqa), Placebo matching darolutamide, ADT; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 985 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 25
States / cities: Phoenix, Arizona • Duarte, California • Los Angeles, California + 18 more

Conditions: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, PSA Progression, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions: Cytology Specimen Collection Procedure, Enzalutamide, Laboratory Biomarker Analysis; Other · Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: Male only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 3
States / cities: Los Angeles, California • San Francisco, California • Portland, Oregon

Conditions: Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Ovarian Cancer, Head Neck Squamous Cell Carcinoma, Prostate Cancer
Interventions: NGM120 30mg, NGM120 100mg, NGM120 30mg with Gemcitabine and Abraxane, NGM120 100mg with Gemcitabine and Abraxane, NGM120 100mg Q3W, Placebo; Biological · Other
Lead sponsor: NGM Biopharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 20
States / cities: Tucson, Arizona • Los Angeles, California • Sacramento, California + 16 more

Conditions: Prostate Cancer
Interventions: Abiraterone, Apitolisib, Ipatasertib, Placebo, Prednisone, Prednisolone; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 12
States / cities: Scottsdale, Arizona • San Francisco, California • Fort Myers, Florida + 9 more

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: XL092; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: 18F-fluciclovine PET Scan; Drug
Lead sponsor: Tulane University; Other
Eligibility: 18 Years to 18 Years · Male only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Oligometastatic Prostate Cancer
Interventions: Stereotactic radiation; Radiation
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older · Male only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: SPECT/CT; Diagnostic Test
Lead sponsor: BAMF Health; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Prostate Cancer, Hormone Refractory Prostate Cancer
Interventions: MDV3100; Drug
Lead sponsor: Pfizer; Industry
Eligibility: Male only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 9
States / cities: Boston, Massachusetts • New York, New York • Portland, Oregon + 2 more

Conditions: Prostate Cancer
Interventions: SBRT; Radiation
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Male only
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Non-Small Cell Lung Cancer, Renal Cell Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Cervical Cancer, Ovarian Cancer, Pancreatic Cancer, Endometrial Cancer, Sarcoma, Squamous Cell Carcinoma of the Head and Neck, Bladder Cancer, Metastatic Castration Resistant Prostate Cancer, Non-hodgkin Lymphoma
Interventions: CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab; Drug
Lead sponsor: Corvus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 22
States / cities: Tucson, Arizona • Duarte, California • San Francisco, California + 18 more

Conditions: Prostate Cancer
Interventions: 225Ac-J591, 177Lu-PSMA-617, 68Ga-PSMA-11, 177Lu-PSMA-I&T; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 99 Years · Male only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 2
States / cities: Brooklyn, New York • New York, New York

Conditions: Prostate Cancer
Interventions: EC1169, EC0652; Drug · Other
Lead sponsor: Endocyte; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 6
States / cities: Scottsdale, Arizona • New Haven, Connecticut • New Orleans, Louisiana + 3 more

Conditions: Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions: Pembrolizumab, pTVG-HP Plasmid DNA Vaccine; Biological
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Male only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions: Laboratory Biomarker Analysis, Radiation Therapy; Other · Radiation
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 2
States / cities: Buffalo, New York • Cheektowaga, New York

Search by objective public record fields.

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma

Imaging Biomarkers to Validate Response in Enzalutamide-Treated mCRPC

A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described

PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery

Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)

Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer

A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies

Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy

XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer

18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies

Radiotherapy for Oligometastatic Prostate Cancer

Use of SPECT-CT for Comparison of Dosimetry Methods in PSMA-targeted Radioligand Therapy (SPECTacular Study)

A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer

SBRT for Oligometastatic Castration-Refractory Prostate Cancer

CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers

Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer

Phase 1 of EC1169 In Patients With Recurrent MCRPC

Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer

Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T